Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis

The Potential of Cell-Penetrating Peptides for mRNA Delivery to Cancer Cells

“…On the other hand, the treatment of STR-Arg8, p5RHH and RALA complexes induced EGFP expressions of 14.6, 86.5 and 29.5%, respectively. Notably, the transfection efficiency of p5RHH was as effective as that of Lipofectamine, and this result is consistent with previous reports that p5RHH/siRNA or mRNA nanocomplexes effectively facilitate endosomal lysis and escape of RNAs into the cytoplasm [40,51]. However, STR-Arg8 and RALA showed relatively low expression efficiency despite a high cellular uptake rate of >85%.…”

“…The cationic CPPs (Arg8, TAT and LMWP) have been extensively studied in the field of gene delivery because they can form nanosized particles with nucleic acids through their cationic properties [33][34][35][36][37][38]. The amphipathic CPPs (p5RHH, RALA, Pep-1 and Penetratin) have also been found to be efficient delivery vehicles for DNA and/or RNA because they can interact with nucleic acids as cationic moieties [23,39,40] and exhibit strong hydrophobic interactions with cell membranes [41]. Additionally, in order to confirm the effect of hydrophobicity in CPP, STR-Arg8 in which a hydrophobic stearyl moiety was introduced into a cationic Arg8 was also investigated.…”

Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells

“…miRNA is a single‐stranded noncoding RNA with a length of 19–24 nucleotides that can regulate cell proliferation, differentiation, migration, and apoptosis (Chen et al, 2019; Van Roosbroeck & Calin, 2017). The miRNA binds to the 3′‐untranslated region (3′‐UTR) of the target messenger RNA (mRNA) through complementary base pairing during posttranscriptional modification, which ultimately cleaves or degrades the target mRNA (Lockhart et al, 2021). Moreover, miRNAs are considered to be oncogene or tumor suppressors in the development of cancers (Gasparello et al, 2020; Han et al, 2019; Li et al, 2017), including CRC.…”

Nanotechnology for cardiovascular diseases

“…synthesized p5RHH nanoparticles loaded with the cyclin-dependent kinase inhibitor p27Kip1 miRNA switch containing the complementary target sequence of miR-126 at its 5′ UTR. 157 This cell-selective nanotherapy significantly reduced neointima formation after wire injury and allowed reendothelialization in vivo , exhibiting potential capacity for treating neointimal hyperplasia, atherosclerosis, and restenosis.…”